Merck KGaA, trading on the OTCMKTS as MKGAY, is a German-based multinational science and technology company with core operations in healthcare, life science and performance materials. Headquartered in Darmstadt, Germany, the company focuses on pharmaceutical research, manufacturing of laboratory reagents and specialty chemicals for diverse industrial applications.
In its healthcare segment, Merck KGaA develops prescription medicines and therapies targeting oncology, immunology, neurology and fertility. Its product portfolio includes monoclonal antibodies, small-molecule drugs and biosimilars designed to address critical unmet medical needs. Through an integrated network of research centers and clinical development sites, the company advances novel drug candidates from discovery through regulatory approval.
The life science division provides tools and consumables for laboratories and biopharmaceutical production, including cell culture media, chromatography resins and analytical instruments. This unit serves academic institutions, contract development and manufacturing organizations (CDMOs) and the biopharma industry, supporting workflows from basic research to commercial manufacturing. The performance materials arm supplies high-performance solutions such as liquid crystals for display technologies, specialty pigments, semiconductor materials and advanced coatings used in electronics, automotive and packaging sectors.
Founded in 1668, Merck KGaA is one of the world’s oldest pharmaceutical and chemical companies, remaining largely family-owned throughout its history. The company operates in over 60 countries and serves customers in more than 190 territories. Since May 2021, Belén Garijo has served as Chair of the Executive Board and CEO, steering the organization’s global strategy and innovation agenda while upholding its long-standing heritage of scientific excellence.
AI Generated. May Contain Errors.